These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 10942772

  • 21. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease.
    Uversky VN, Li J, Bower K, Fink AL.
    Neurotoxicology; 2002 Oct; 23(4-5):527-36. PubMed ID: 12428725
    [Abstract] [Full Text] [Related]

  • 22. Parkinson's disease-associated alpha-synuclein is a calmodulin substrate.
    Martinez J, Moeller I, Erdjument-Bromage H, Tempst P, Lauring B.
    J Biol Chem; 2003 May 09; 278(19):17379-87. PubMed ID: 12610000
    [Abstract] [Full Text] [Related]

  • 23. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
    Shtilerman MD, Ding TT, Lansbury PT.
    Biochemistry; 2002 Mar 26; 41(12):3855-60. PubMed ID: 11900526
    [Abstract] [Full Text] [Related]

  • 24. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T.
    Am J Pathol; 1998 Apr 26; 152(4):879-84. PubMed ID: 9546347
    [Abstract] [Full Text] [Related]

  • 25. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.
    Uversky VN, Eliezer D.
    Curr Protein Pept Sci; 2009 Oct 26; 10(5):483-99. PubMed ID: 19538146
    [Abstract] [Full Text] [Related]

  • 26. Accumulation of beta- and gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1-deficient gad mouse.
    Wang YL, Takeda A, Osaka H, Hara Y, Furuta A, Setsuie R, Sun YJ, Kwon J, Sato Y, Sakurai M, Noda M, Yoshikawa Y, Wada K.
    Brain Res; 2004 Sep 03; 1019(1-2):1-9. PubMed ID: 15306232
    [Abstract] [Full Text] [Related]

  • 27. Exploring Intrinsic Disorder in Human Synucleins and Associated Proteins.
    Venati SR, Uversky VN.
    Int J Mol Sci; 2024 Aug 01; 25(15):. PubMed ID: 39125972
    [Abstract] [Full Text] [Related]

  • 28. A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins.
    Syme CD, Blanch EW, Holt C, Jakes R, Goedert M, Hecht L, Barron LD.
    Eur J Biochem; 2002 Jan 01; 269(1):148-56. PubMed ID: 11784308
    [Abstract] [Full Text] [Related]

  • 29. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT.
    Proc Natl Acad Sci U S A; 2000 Jan 18; 97(2):571-6. PubMed ID: 10639120
    [Abstract] [Full Text] [Related]

  • 30. Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease.
    Hegde ML, Jagannatha Rao KS.
    Arch Biochem Biophys; 2003 Oct 15; 418(2):169-78. PubMed ID: 14522588
    [Abstract] [Full Text] [Related]

  • 31. Evidence for a partially folded intermediate in alpha-synuclein fibril formation.
    Uversky VN, Li J, Fink AL.
    J Biol Chem; 2001 Apr 06; 276(14):10737-44. PubMed ID: 11152691
    [Abstract] [Full Text] [Related]

  • 32. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA, Harper JD, Lansbury PT.
    Nat Med; 1998 Nov 06; 4(11):1318-20. PubMed ID: 9809558
    [Abstract] [Full Text] [Related]

  • 33. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.
    Kessler JC, Rochet JC, Lansbury PT.
    Biochemistry; 2003 Jan 28; 42(3):672-8. PubMed ID: 12534279
    [Abstract] [Full Text] [Related]

  • 34. Forcing nonamyloidogenic beta-synuclein to fibrillate.
    Yamin G, Munishkina LA, Karymov MA, Lyubchenko YL, Uversky VN, Fink AL.
    Biochemistry; 2005 Jun 28; 44(25):9096-107. PubMed ID: 15966733
    [Abstract] [Full Text] [Related]

  • 35. Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation.
    Sode K, Usuzaka E, Kobayashi N, Ochiai S.
    Biochem Biophys Res Commun; 2005 Sep 23; 335(2):432-6. PubMed ID: 16081040
    [Abstract] [Full Text] [Related]

  • 36. Dependence of alpha-synuclein aggregate morphology on solution conditions.
    Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V.
    J Mol Biol; 2002 Sep 13; 322(2):383-93. PubMed ID: 12217698
    [Abstract] [Full Text] [Related]

  • 37. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
    Bickle L, Hopwood JJ, Karageorgos L.
    Biochim Biophys Acta Proteins Proteom; 2017 Mar 13; 1865(3):261-273. PubMed ID: 28007442
    [Abstract] [Full Text] [Related]

  • 38. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease.
    Clayton DF, George JM.
    Trends Neurosci; 1998 Jun 13; 21(6):249-54. PubMed ID: 9641537
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
    Rochet JC, Conway KA, Lansbury PT.
    Biochemistry; 2000 Sep 05; 39(35):10619-26. PubMed ID: 10978144
    [Abstract] [Full Text] [Related]

  • 40. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.
    Kahle PJ, Neumann M, Ozmen L, Haass C.
    Ann N Y Acad Sci; 2000 Sep 05; 920():33-41. PubMed ID: 11193173
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.